AstraZeneca walks back some of its immuno-oncology ambition

Damian Garde

, working to catch up with Merck and Bristol-Myers Squibb in the growing field of immuno-oncology, said its treatment is unlikely to win speedy approval in lung cancer due to the presence of more advanced agents.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS